文献速递胸部肿瘤头颈与中枢神经肿瘤

酪氨酸激酶抑制剂初治的表皮生长因子受体突变非小细胞肺癌脑转移的管理:一项回顾性多机构分析

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
PubMed 文献 · J Clin Oncol · 2017-01-23

这项回顾性多机构分析纳入351例未接受过EGFR-TKI的EGFR突变非小细胞肺癌脑转移患者,比较SRS后EGFR-TKI、WBRT后EGFR-TKI与EGFR-TKI后延迟放疗三种策略。SRS组中位OS最长(46个月),WBRT组30个月,EGFR-TKI组25个月(P<.001)。作者结论认为 upfront EGFR-TKI并延迟放疗与较差OS相关,SRS后EGFR-TKI带来最长OS。

要点

  • SRS后EGFR-TKI组中位OS为46个月,优于WBRT后EGFR-TKI组的30个月和EGFR-TKI后延迟放疗组的25个月(P<.001)。
  • 多因素分析中,SRS对比EGFR-TKI、WBRT对比EGFR-TKI、年龄、体能状态、EGFR外显子19突变及无颅外转移与OS改善相关。
  • 作者结论认为 upfront EGFR-TKI并延迟放疗与较差OS相关,SRS后EGFR-TKI带来最长OS并避免WBRT神经认知后遗症。

核心结论

  • 这项多机构分析表明,在EGFR突变非小细胞肺癌脑转移患者中,upfront EGFR-TKI并延迟放疗与较差的OS相关。
  • SRS后EGFR-TKI带来最长OS,并使患者避免WBRT可能的神经认知后遗症。
  • 作者认为亟需开展SRS后EGFR-TKI对比颅内进展时EGFR-TKI后SRS的前瞻性多机构随机试验。

研究设计与样本

  • 回顾性多机构分析,纳入6家机构的351例EGFR突变非小细胞肺癌脑转移患者。
  • 排除标准包括既往EGFR-TKI使用、EGFR-TKI耐药突变、WBRT/SRS后未接受EGFR-TKI或随访不足。
  • 患者接受SRS后EGFR-TKI(n=100)、WBRT后EGFR-TKI(n=120)或EGFR-TKI后在颅内进展时行SRS或WBRT(n=131)。
  • OS和颅内无进展生存期自脑转移诊断日期起计算。

主要发现

  • SRS组(n=100)、WBRT组(n=120)和EGFR-TKI组(n=131)的中位OS分别为46、30和25个月(P<.001)。
  • 多因素分析中,SRS对比EGFR-TKI、WBRT对比EGFR-TKI、年龄、体能状态、EGFR外显子19突变及无颅外转移与OS改善相关。
  • SRS组与EGFR-TKI组共享相似的预后特征,而WBRT组更可能预后较差(P=.001)。

临床怎么用

  • 作者结论认为upfront EGFR-TKI并延迟放疗与较差OS相关,SRS后EGFR-TKI带来最长OS。
  • 作者认为亟需开展SRS后EGFR-TKI对比颅内进展时EGFR-TKI后SRS的前瞻性多机构随机试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for brain metastases in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). This multi-institutional analysis sought to determine the optimal management of patients with EGFR-mutant NSCLC who develop brain metastases and have not received EGFR-TKI. Materials and Methods A total of 351 patients from six institutions with EGFR-mutant NSCLC developed brain metastases and met inclusion criteria for the study. Exclusion criteria included prior EGFR-TKI use, EGFR-TKI resistance mutation, failure to receive EGFR-TKI after WBRT/SRS, or insufficient follow-up. Patients were treated with SRS followed by EGFR-TKI, WBRT followed by EGFR-TKI, or EGFR-TKI followed by SRS or WBRT at intracranial progression. Overall survival (OS) and intracranial progression-free survival were measured from the date of brain metastases. Results The median OS for the SRS (n = 100), WBRT (n = 120), and EGFR-TKI (n = 131) cohorts was 46, 30, and 25 months, respectively ( P < .001). On multivariable analysis, SRS versus EGFR-TKI, WBRT versus EGFR-TKI, age, performance status, EGFR exon 19 mutation, and absence of extracranial metastases were associated with improved OS. Although the SRS and EGFR-TKI cohorts shared similar prognostic features, the WBRT cohort was more likely to have a less favorable prognosis ( P = .001). Conclusion This multi-institutional analysis demonstrated that the use of upfront EGFR-TKI, and deferral of radiotherapy, is associated with inferior OS in patients with EGFR-mutant NSCLC who develop brain metastases. SRS followed by EGFR-TKI resulted in the longest OS and allowed patients to avoid the potential neurocognitive sequelae of WBRT. A prospective, multi-institutional randomized trial of SRS followed by EGFR-TKI versus EGFR-TKI followed by SRS at intracranial progression is urgently needed.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Magnuson WJ, Lester-Coll NH, Wu AJ, et al. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. J Clin Oncol. 2017. PMID: 28113019. doi:10.1200/JCO.2016.69.7144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。